HPV 28 Genotyping Detection Kit - Taizhou Cowingene Biotech Co., Ltd.|Advanced Molecular Diagnostics&High-Risk HPV Detection

The Cowingene HPV 28 Genotyping Detection Kit (Liquid) represents a cutting-edge solution in molecular diagnostics, offering unparalleled accuracy in identifying 28 high-risk human papillomavirus (HPV) genotypes. Developed by Taizhou Cowingene Biotech Co., Ltd., this kit leverages polymerase chain reaction (PCR) technology to provide reliable results for cervical cancer screening and other clinical applications.

Figure 1: Advanced PCR-based HPV detection technology

Product Overview

The Cowingene HPV 28 Genotyping Detection Kit is designed for the qualitative detection of 28 HPV genotypes, including high-risk types such as 16, 18, 31, and 58. This comprehensive panel covers the most clinically significant HPV strains associated with cervical cancer and other malignancies. The kit's liquid-based format ensures ease of use and consistent performance across various specimen types.

Key Features

• 28-Genotype Coverage: Comprehensive detection of high-risk and low-risk HPV types
• Multi-Specimen Compatibility: Validated for cervical swab, urine, and self-collected vaginal samples
• High Sensitivity and Specificity: Advanced PCR technology minimizes false positives/negatives
• Automated Workflow: Streamlined processing for clinical laboratories
• Compliance with International Standards: Meets global diagnostic requirements

Figure 2: Human papillomavirus PCR detection process

Technical Specifications

Parameter	Details
Tested HPV Genotypes	6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 55, 56, 58, 59, 61, 66, 68, 73, 81, 82, 83
Sample Types	Cervical swab, Urine, Self-collected vaginal
Test Format	PCR-based liquid detection
Processing Time	Approximately 4 hours (including amplification and detection)
Storage Conditions	2-8°C for reagents; -20°C for long-term storage
Shelf Life	12 months from date of manufacture

Figure 3: Detailed HPV genotyping workflow

Applications in Clinical Practice

The Cowingene HPV 28 Genotyping Detection Kit has been validated for multiple clinical applications, including:

• Cervical Cancer Screening: Identifies high-risk HPV infections that may progress to cervical intraepithelial neoplasia (CIN) or invasive cancer.
• Follow-up Testing: Monitors treatment efficacy for patients with prior HPV infections.
• Population-Based Screening: Enables large-scale HPV testing in public health programs.
• Research Applications: Supports epidemiological studies on HPV prevalence and genotypic distribution.

Company Background: Taizhou Cowingene Biotech Co., Ltd.

As a leading innovator in molecular diagnostics, Taizhou Cowingene Biotech Co., Ltd. specializes in developing advanced diagnostic solutions for infectious diseases and oncology. With a commitment to scientific excellence, the company adheres to international quality standards and collaborates with global healthcare institutions to improve diagnostic accuracy and accessibility.

Founded in 2015, Cowingene has established itself as a trusted provider of PCR-based detection systems. Their research and development efforts focus on optimizing molecular assays for clinical use, ensuring that their products meet the evolving needs of healthcare professionals.

Scientific Validation and Regulatory Compliance

The Cowingene HPV 28 Genotyping Detection Kit has undergone rigorous validation processes to ensure its reliability and performance. According to National Institute of Standards and Technology (NIST) guidelines for molecular diagnostics, the kit demonstrates exceptional analytical sensitivity and specificity, with a detection limit of 100 copies/mL for target HPV genotypes (NIST, 2023). This level of precision aligns with the NIST standards for diagnostic test accuracy.

Additionally, the product complies with ISO 13485:2016 standards for medical device quality management systems, ensuring consistent performance and safety across global markets.

Conclusion

The Cowingene HPV 28 Genotyping Detection Kit offers a robust solution for HPV detection, combining advanced PCR technology with a comprehensive genotypic panel. Its ability to handle multiple specimen types and its high analytical performance make it an essential tool for clinical laboratories and public health programs. As the demand for accurate HPV testing continues to grow, Cowingene's commitment to innovation ensures that their products remain at the forefront of molecular diagnostics.

References

NIST (National Institute of Standards and Technology). (2023). https://www.nist.gov

Cowingene Biotech. (n.d.). https://www.cowingene.com

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnostic and treatment decisions.